Commercial feasibility of a therapeutic approach to cancer based on ‘LEGO’ antibody recruiting glycodendrimers

Project description

LEGO-based immunotherapics against cancer

Cancer incidence is rising globally, and despite advances in treatments, there are many side effects that hamper their effectiveness. Immunotherapy has emerged as a promising anticancer strategy, but efficacy and toxicity issues remain to be addressed. The EU-funded THERA-LEGO project will build on previous experience to produce antibody recruiting glycodendrimers (ARGs) using a molecular LEGO approach capable of binding endogenous antibodies and redirecting them against tumours. ARGs form ternary complexes with cancer cells, causing cell death. Scientists will screen these synthetic ARG structures in humanised models of cancer before proceeding with clinical development.

Fields of science

• medical and health sciences › clinical medicine › cancer

Programme(s)

• H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC)

Topic(s)

• ERC-2020-POC - Call for proposals for ERC Proof of Concept Grant

Call for proposal

ERC-2020-PoC
See other projects for this call

Funding Scheme

ERC-POC-LS - ERC Proof of Concept Lump Sum Pilot

Host institution

UNIVERSITE GRENOBLE ALPES

Address

621 Avenue Centrale
38058 Grenoble
France

Activity type

Higher or Secondary Education Establishments

EU contribution

€ 150 000

Beneficiaries (1)

UNIVERSITE GRENOBLE ALPES

France

EU contribution

€ 150 000

Address

621 Avenue Centrale
38058 Grenoble

Activity type

Higher or Secondary Education Establishments